AbbVie Inc. (ABBV)

From a risk management standpoint, AbbVie's transition past the Humira patent cliff is fundamentally complete, but new capital allocation choices warrant caution. The planned Apogee Therapeutics acquisition introduces near-term earnings dilution and IP RandD milestone expenses of $0.17 per share. Coupled with elevated leverage, capital flexibility could remain constrained through the back half of the fiscal year.

On our desk, we are seeing a stark disconnect between Wall Street's 77% buy consensus and the retail crowd's hesitation, with Polymarket sentiment sitting at a bearish 27%. While Q2 net revenues beat internal expectations by $300 million and adjusted EPS hit $3.65, off-exchange dark pool short volume nearing 56% suggests institutional hesitation around valuation limits and high debt levels.

As a bio-analyst reviewing the latest transcripts, management's decision to raise full-year revenue guidance to approximately $67.6 billion underscores strong confidence in neuroscience and immunology. However, SeekingAlpha and other independent commentators rightly point out that high debt from past and ongoing pipeline expansion limits multiple expansion, keeping shares at a perceived fair-value hold.

In our clinic, the prescription momentum for Skyrizi and Rinvoq remains exceptionally robust, perfectly mirroring the global net revenue figures reported in Q2 2026 where Skyrizi delivered $5.505 billion and Rinvoq reached $2.525 billion. Even with legacy Humira dropping down to $756 million globally, the immunology portfolio's total surge to $8.786 billion confirms our real-world clinical observations.

As a hedge fund PM, my focus is squarely on whether AbbVie can sustain its growth engines without sacrificing margin stability. Q2 GAAP diluted EPS jumped over 290% to $2.03, but adjusted EPS growth was a more modest 22.9% at $3.65. The market is pricing in a bright future, but at current valuation multiples, much of that operational excellence is already baked into the price.